Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?

Seminars in Oncology

Volumn 31, Issue SUPPL. 18, 2004, Pages 52-58

  Rosenman, Julian ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; VINBLASTINE;

CLINICAL TRIAL; CONFERENCE PAPER; ESOPHAGITIS; HUMAN; LUNG NON SMALL CELL CANCER; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA;

EID: 13844292675     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.12.013     Document Type: Conference Paper

References (41)

1. A. Jemal, R.C. Tiwari, T. Murray Cancer Statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. S. Bhatia, N. Hanna, R. Ansari Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study Lung Cancer 38 2002 85 89
3. R.O. Dillman, S.L. Seagren, K.J. Propert A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer N Engl J Med 323 1990 940 945
4. K. Furuse, M. Fukuoka, M. Kawahara Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer J Clin Oncol 17 1999 2692 2699
5. W.J. Curran Jr, C. Scott, C. Langer Phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer (NSCLC) Initial report of Radiation Therapy Oncology Group (RTOG) 9410 Proc Am Soc Clin Oncol 19 2000 484a (abstr 1891)
6. F. Pierre, P. Maurice, R. Gilles A randomized phase III trial of sequential chemoradiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study) Proc Am Soc Clin Oncol 20 2001 312A (abstr 1246)
7. P. Zatloukal, L. Petruzelka, M. Zemanova Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer A randomized study Lung Cancer 46 2004 87 98
8. R.M. Huber, M. Schmidt, M. Flentje BROCAT-Group Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (stage IIIa/IIIb) Proc Am Soc Clin Oncol 22 2003 622 (abstr 2501)
9. H. Choy, W.J. Curran Jr., C.B. Scott Preliminary report of locally advanced multimodality protocol (LAMP): ACR 427: A randomized phase II study of three chemoradiation regimens with paclitaxel, carboplatin, and thoracic radiation for patients with locally advanced non small cell lung cancer (LA-NSCLC) Proc Am Soc Clin Oncol 21 2002 291a (abstr 1160)
10. T. LeChevalier, R. Arriagada, E. Quoix Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer First analysis of a randomized trial in 353 patients J Natl Cancer Inst 83 1991 417 423
11. C.A. Perez, T.F. Pajak, P. Rubin Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group Cancer 59 1987 1874 1881
12. P. Tai, E. Yu, J. Battista Radiation treatment of lung cancer--Patterns of practice in Canada Radiother Oncol 71 2004 167 174
13. J. Cox, N. Azarnia, R. Byhardt N2 (clinical) non-small cell carcinoma of the lung Prospective trials of radiation therapy with total doses < 60 Gy by the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 20 1991 7 12
14. W. Sause, P. Kolesar, S. Taylor Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588 Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer Chest 117 2000 358 364
15. M.P. Mehta, W. Wang, D. Johnson Induction chemotherapy followed by standard thoracic radiotherapy vs. hyperfractionated accelerated radiotherapy in patients with unresectable stage IIIA and B non-small-cell lung cancer Phase III study of the eastern cooperative oncology (ECOG 2597) Int J Radiat Oncol Biol Phys 57 SUPPL. 1 2003 S141
16. J.G. Rosenman, J.S. Halle, M.A. Socinski High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer Technical issues and results of a phase I/II trial Int J Radiat Oncol Biol Phys 54 2002 348 356
17. M. Saunders, S. Dische, A. Barrett Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer A randomized multicentre trial Lancet 350 1997 161 165
18. K.E. Rosenzweig, B. Mychalczak, Z. Fuks Final report of the 70.2-Gy and 75.6-Gy dose levels of a phase I dose escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small cell lung cancer Cancer J 6 2000 82 87
19. J.S. Belderbos, K. De Jaeger, W.D. Heemsbergen First results of a phase I/II dose escalation trial in non-small cell lung cancer using three-dimensional conformal radiotherapy Radiother Oncol 66 2003 119 126
20. P.D. Maguire, L.B. Marks, G.S. Sibley 73.6 Gy and beyond Hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer J Clin Oncol 19 2001 705 711
21. J.A. Hayman, M.K. Martel, R.K. Ten Haken Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy Update of a phase I trial J Clin Oncol 19 2001 127 136
22. A.K. Singh, M.A. Lockett, J.D. Bradley Predictors of radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with three-dimensional conformal radiotherapy Int J Radiat Oncol Biol Phys 55 2003 337 341
23. R.W. Byhardt, C. Scott, W.T. Sause Response, toxicity, failure patterns, and survival in five radiation therapy oncology group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung Int J Radiat Oncol Biol Phys 42 1998 469 478
24. L.B. Marks, J. Garst, M.A. Socinski Carboplatin/Paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy Report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium J Clin Oncol 22 2004 4329 4340
25. J.K. LeBlanc, R. Espada, G. Erqun Non-small cell lung cancer staging techniques and endoscopic ultrasound Tissue is still the issue Chest 123 2003 1718 1725
26. M.V. Graham, J.A. Purdy, B. Emami Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer Int J Radiat Oncol Biol Phys 33 1995 993 1000
27. L.B. Marks Dosimetric predictors of radiation-induced lung injury Int J Radiat Oncol Biol Phys 54 2002 313 316
28. P.D. Maguire, G.S. Sibley, S.M. Zhou Clinical and dosimetric predictors of radiation-induced esophageal toxicity Int J Radiat Oncol Biol Phys 45 1999 97 103
29. R. Komaki, W. Seiferheld, D. Ettinger Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer Long-term follow-up of RTOG 92-04 Int J Radiat Oncol Biol Phys 53 2002 548 557
30. M. Werner-Wasik, E. Pequignot, D. Leeper Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus A multivariate analysis of patients with lung cancer treated with nonoperative therapy Int J Radiat Oncol Biol Phys 48 2000 689 696
31. S. Ahn, D.A. Kahn, S. Zhou Dosimetric parameters predictive for esophageal injury Int J Radiat Oncol Biol Phys 57 SUPPL. 1 2003 S217
32. R. Komaki, J.S. Lee, L. Milas Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer Report of a randomized comparative trial Int J Radiat Oncol Biol Phys 58 2004 1369 1377
33. D. Antonadou Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer Semin Radiat Oncol 12 SUPPL. 1 2002 50 58
34. B. Movsas, C. Scott, C. Langer Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy & hyperfractionated radiation (chemo/HFxRT) Radiation Therapy Oncology Group (RTOG) 98-01 Proc Am Soc Clin Oncol 22 2003 636 (abstr 2559)
35. M. Werner-Wasik, C. Scott, W.J. Curran Jr Correlation between acute esophagitis and late pneumonitis in patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) receiving concurrent thoracic radiotherapy (RT) and chemotherapy A multivariate analysis of the Radiation Therapy Oncology Group (RTOG) database Proc Am Soc Clin Oncol 21 2002 299a (abstr 1192)
36. N.K. Aaronson, S. Ahmedzai, B. Bergman The European Organization for Research and Treatment of Cancer QLQC30 A quality of life instrument for use in international clinical trials in oncology J Natl Cancer Inst 85 1993 365 376
37. N.K. Aaronson, W. Bakker, A.L. Stewart Multidimensional approach to the measurement of quality of life in lung cancer clinical trials N.K. Aaronson J. Beckman Quality of Life in Cancer Patients 1987 Raven Press New York, NY 63 82
38. D. Osoba, N.K. Aaronson, B. Zee The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer Qual Life Res 6 1997 103 108
39. B. Bergman, N.K. Aaronson, S. Ahmedzai EORTC Study Group on Quality of Life The EORTC QLQ-LC-13 A questionnaire (QLQ-C30) for use in lung cancer clinical trials Eur J Cancer 30A 1994 635 642
40. S. Kaasa The EORTC quality of life questionnaires R. Gralla C.M. Moinpour Assessing Quality of Life in Patients with Lung Cancer A Guide for Clinicians 1995 NCM Publishers Inc New York, NY xx-xx
41. S. Kaasa, K. Bjordal, N.K. Aaronson The EORTC core quality of life questionnaire (QLQ C30) Validity and reliability when analysed with patients treated with palliative radiotherapy Eur J Cancer 31A 1995 2260 2263